Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.83 |
| ▸ | HPGD | P15428 | 9/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | RUVBL1 | Q9Y265 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RUVBL2 | Q9Y230 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902537 | 0.93 | ALDH1A1 (0.72) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902549 | 0.92 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902315 | 0.90 | KDM4E (0.84) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902125 | 0.85 | HSD17B10 (0.65) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902339 | 0.85 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL26003171 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902657 | 0.82 | TP53 (0.60) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL15274740 | 0.82 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902719 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL902729 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| EP-2621928-A1 | 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041817-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | ALDH1A1 441/4885KDM4E 4265/4885HPGD 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.